Vistagen to Present at Key Investor Conferences in March 2026
Event summary
- Vistagen (Nasdaq: VTGN) will participate in two investor conferences in March 2026.
- Leerink Healthcare Conference (March 9-11, 2026) in Miami, FL, will feature one-on-one meetings.
- Stifel 2026 Virtual CNS Forum (March 17, 2026) will include a fireside chat with CEO Shawn Singh and one-on-one meetings.
- Stifel presentation will be webcast live and available for replay on Vistagen’s Investor Relations page.
The big picture
Vistagen’s participation in high-profile investor conferences underscores its push to engage with key stakeholders as it advances its intranasal pherine candidates. The focus on one-on-one meetings and a fireside chat suggests a strategic effort to build investor confidence amid a competitive landscape in neuroscience therapeutics. The company’s emphasis on rapid-onset, non-invasive treatments positions it within broader industry trends toward safer, more targeted neurological interventions.
What we're watching
- Pipeline Progress
- How Vistagen’s participation in these conferences will impact investor perception of its late-stage clinical pipeline.
- Market Positioning
- Whether Vistagen can differentiate its pherine product candidates in a competitive neuroscience market.
- Execution Risk
- The pace at which Vistagen advances its product candidates through clinical trials and regulatory approvals.
Related topics